Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma

British Journal of Haematology

Volumn 151, Issue 1, 2010, Pages 92-93

  Lund, Thomas ^a,b   Abildgaard, Niels ^c   Delaisse, Jean Marie ^b   Plesner, Torben ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

bisphosphonate; CTX; multiple myeloma; NTX; osteonecrosis of the jaw

Indexed keywords

COLLAGEN TYPE 1; PROTEIN NTX 1; TELOPEPTIDE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; AGED; BONE DISEASE; BONE REMODELING; DRUG WITHDRAWAL; FEMALE; HUMAN; JAW OSTEONECROSIS; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; BLOOD; COMPLICATION; DRUG ADMINISTRATION; DRUG EFFECTS; MIDDLE AGED; PREVENTION AND CONTROL; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE RESORPTION; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES;

EID: 77956842751     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08293.x     Document Type: Letter

References (10)

1. Abildgaard, N., Brixen, K., Kristensen, J.E., Eriksen, E.F., Nielsen, J.L. Heickendorff, L. (2003) Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. British Journal of Haematology, 120, 235 242.
2. Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M.J., Blacklock, H.A., Bell, R., Simeone, J., Reitsma, D.J., Heffernan, M., Seaman, J. Knight, R.D. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. The New England Journal of Medicine, 334, 488 493.
3. Corso, A., Varettoni, M., Zappasodi, P., Klersy, C., Mangiacavalli, S., Pica, G. Lazzarino, M. (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia, 21, 1545 1548.
4. Durie, B.G. (2007) Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clinic Proceedings, 82, 516 517.
5. Kyle, R.A., Yee, G.C., Somerfield, M.R., Flynn, P.J., Halabi, S., Jagannath, S., Orlowski, R.Z., Roodman, D.G., Twilde, P. Anderson, K. (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. Journal of Clinical Oncology, 25, 2464 2472. (Pubitemid 46999218)
6. Lacy, M.Q., Dispenzieri, A., Gertz, M.A., Greipp, P.R., Gollbach, K.L., Hayman, S.R., Kumar, S., Lust, J.A., Rajkumar, S.V., Russell, S.J., Witzig, T.E., Zeldenrust, S.R., Dingli, D., Bergsagel, P.L., Fonseca, R., Reeder, C.B., Stewart, A.K., Roy, V., Dalton, R.J., Carr, A.B., Kademani, D., Keller, E.E., Viozzi, C.F. Kyle, R.A. (2006) Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clinic Proceedings, 81, 1047 1053.
7. Lipton, A., Cook, R.J., Coleman, R.E., Smith, M.R., Major, P., Terpos, E. Berenson, J.R. (2007) Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clinical Lymphoma & Myeloma, 7, 346 353.
8. Lund, T., Abildgaard, N., Andersen, T.L., Delaisse, J.M. Plesner, T. (2010) Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. European Journal of Haematology, 84, 412 420.
9. Rosen, L.S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M.A., Coleman, R.E., Reitsma, D.J., Chen, B.L. Seaman, J.J. (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 98, 1735 1744.
10. Terpos, E., Sezer, O., Croucher, P.I., Garcia-Sanz, R., Boccadoro, M., San, M.J., Ashcroft, J., Blade, J., Cavo, M., Delforge, M., Dimopoulos, M.A., Facon, T., Macro, M., Waage, A. Sonneveld, P. (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Annals of Oncology, 20, 1303 1317.